FL-ZEROCHAOS
ZeroChaos, a global provider of workforce management solutions, announced today the 2018 Proven Performers in its Performance Excellence Program. The award recognizes 42 organizations for talent management initiatives that had significant, measurable business impact on ZeroChaos’ customer programs.
“We are thrilled each year by our community of trusted, high-performance partners who support ZeroChaos’ values and are committed to the success of our customer programs,” said Karen Maarouf, vice president of supplier relations for ZeroChaos, “and this year was no different. All of the award recipients are advancing ZeroChaos’ mission of transforming contingent workforce management, and it is our privilege to recognize their outstanding work.”
ZeroChaos’ Performance Excellence program was established in 2016 to foster, recognize, and reward excellence in providing contingent staffing services for ZeroChaos customer programs worldwide. Each year, Proven Performers are identified based on a set of metrics including participation analytics, cycle time, talent quality, program compliance, and more.
“Avispa Technology is thrilled to be recognized as a 2018 Proven Performer by ZeroChaos, our premiere VMS partner, for a third consecutive year,” said Rothman Moncayo, President & CEO for Avispa Technology, “and we are so thankful to ZeroChaos for recognizing our commitment to your programs and for the opportunity to support world-class clients. We value our partnership and always stand ready to serve additional programs.”
The list of award recipients includes:
- Ampcus Inc.
- ASK Staffing, Inc.
- Avispa Technology
- Axelon Services Corp.
- Capital Staffing Solutions
- Career Group Companies
- Catapult Staffing, LLC.
- Collabera
- Cypress HCM
- eTeam, Inc.
- Flexton Inc.
- HCS Healthcare
- Integrated Resources Inc.
- Intelliswift Software Inc.
- IT Optimiser
- Lancesoft
- MATRIX
- MINDLANCE, INC.
- Motion Recruitment Partners
- NESC Staffing, LLC.
- NTT DATA SERVICES
- PDS Tech, Inc.
- Primus Software Corporation
- Pyramid Consulting, Inc.
- Rose International, Inc.
- Solomon Page
- Specialist Staffing Group (U.S. Division of SThree PLC)
- SPECTRAFORCE Technologies, Inc.
- Strom Aviation
- Supplemental Health Care
- Systemart, LLC.
- TalentBurst, Inc.
- Tekberry, Inc.
- Ubertal, Inc.
- Ultimate Staffing Services
- United Global Technologies (UGT)
- USPRO
- VARITE, Inc.
- Vertisystem, Inc.
About ZeroChaos
ZeroChaos is a global provider of workforce management solutions that help organizations achieve greater management and financial control of their workforce and talent supply chains. ZeroChaos’ award-winning solutions, including its vendor-neutral Managed Services Program, enable procurement and human resources to improve visibility into contingent labor spend and talent pools, effectively manage and optimize contingent workforce program performance, and mitigate risks. Headquartered in Orlando, ZeroChaos has global operations in the Americas, Europe, and Asia. For more information visit www.zerochaos.com , follow on Twitter @ZeroChaos , or connect with ZeroChaos on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180326005038/en/
Contact:
ZeroChaos
Patricia Braa, 602-763-6886
pbraa@zerochaos.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release
Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release
Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release
New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom